The dichloroacetate dilemma: environmental hazard versus therapeutic goldmine--both or neither?

Peter W Stacpoole, Peter W Stacpoole

Abstract

Background: Dichloroacetate (DCA) is known to environmental scientists as a by-product of water chlorination and as a metabolite of industrial solvents, including Superfund chemicals. In contrast, DCA is studied by clinical investigators for its therapeutic potential in several life-threatening conditions, including genetic mitochondrial diseases, pulmonary arterial hypertension, and cancer. Thus, DCA holds an almost unique position at the interface between environmental science and allopathic medicine.

Objective: I critically reviewed laboratory and clinical pharmacological research on DCA to address questions about the current and future status of DCA in relation to human health.

Discussion: Recent information on the clinical toxicogenetics of DCA is interpreted particularly in light of its use as an investigational drug. Adverse effects from chronic DCA exposure have been identified in several target organs in animals. However, in humans, toxicity has so far been limited to reversible effects on the nervous system and liver. DCA is primarily biotransformed to glyoxylate by the bifunctional enzyme glutathione transferase zeta1 and maleylacetoacetate isomerase (GSTz1/MAAI), which also catalyzes the penultimate step in the phenylalanine and tyrosine catabolic pathway. DCA is a suicide inhibitor of GSTz1/MAAI, which can result in delayed plasma clearance of DCA and the accumulation of potentially toxic tyrosine intermediates. Age and GSTz1/MAAI haplotype can markedly affect the toxicokinetics of DCA in humans and rodents.

Conclusions: I have defined new potential avenues of research that focus on discrete human populations that may be at increased health risk or that may receive increased health benefit from chronic exposure to DCA at both environmentally and clinically relevant concentrations.

References

    1. Agency for Toxic Substances and Disease Registry. Toxic Substances Portal: Trichloroethylene (TCE). Toxicological Profile for Trichloroethylene. Atlanta, GA: Centers for Disease Control and Prevention; 1997. [[accessed 9 September 2010]]. Available: .
    1. Ammini CV, Fernandez-Canon J, Shroads AL, Cornett R, Cheung J, James MO, et al. Pharmacologic or genetic ablation of maleylacetoacetate isomerase increases levels of toxic tyrosine catabolites in rodents. Biochem Pharmacol. 2003;66:2029–2038.
    1. Ammini CV, Stacpoole PW. Biotransformation, toxicology and pharmacogenomics of dichloroacetate. In: Gribble GW, editor. Natural Production of Organohalogen Compounds. Handbook of Environmental Chemistry 3/P. Berlin: Springer; 2003. pp. 215–234.
    1. Anderson WB, Board PG, Anders MW. Glutathione transferase zeta-catalyzed bioactivation of dichloroacetic acid: reaction of glyoxylate with amino acid nucleophiles. Chem Res Toxicol. 2004;17:650–662.
    1. Anderson WB, Board PG, Gargano B, Anders MW. Inactivation of glutathione transferase zeta by dichloroacetic acid and other fluorine-lacking alpha-haloalkanoic acids. Chem Res Toxicol. 1999;12:1144–1149.
    1. Barshop BA, Naviaux RK, McGowan KA, Levine F, Nyhan WL, Loupis-Geller A, et al. Chronic treatment of mitochondrial disease patients with dichloroacetate. Mol Genet Metab. 2004;83:138–149.
    1. Berendzen K, Theriaque D, Shuster J, Stacpoole PW. Therapeutic potential of dichloroacetate for pyruvate dehydrogenase complex deficiency. Mitochondrion. 2006;6:126–135.
    1. Bonnet S, Archer SL, Allalunis-Turner J, Haromy A, Beaulieu C, Thompson R, et al. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell. 2007;11:37–51.
    1. Bonnet S, Michelakis ED, Porter CJ, Andrade-Navarro MA, Thébaud B, Bonnet S, et al. An abnormal mitochondrial-hypoxia inducible factor-1alpha-Kv channel pathway disrupts oxygen sensing and triggers pulmonary arterial hypertension in fawn hooded rats: similarities to human pulmonary arterial hypertension. Circulation. 2006;113:2630–2641.
    1. Bowker-Kinley MM, Davis WI, Wu P, Harris RA, Popov KM. Evidence for existence of tissue-specific regulation of the mammalian pyruvate dehydrogenase complex. Biochem J. 1998;329:191–196.
    1. Brüning T, Pesch B, Wiesenhütter B, Rabstein S, Lammert M, Baumuller A, et al. Renal cell cancer risk and occupational exposure to trichloroethylene: results of a consecutive case–control study in Arnsberg, Germany. Am J Ind Med. 2003;43:274–285.
    1. Charbotel B, Fevotte J, Hours M, Martin JL, Bergeret A. Case–control study on renal cell cancer and occupational exposure to trichloroethylene. Part II: epidemiological aspects. Ann Occup Hyg. 2006;50:777–787.
    1. Chiu WA, Okino MS, Evans MV. Characterizing uncertainty and population variability in the toxicokinetics of trichloroethylene and metabolites in mice, rats, and humans using an updated database, physiologically based pharmacokinetic (PBPK) model, and Bayesian approach. Toxicol Appl Pharmacol. 2009;241:36–60.
    1. Cornett R, James MO, Henderson GN, Cheung J, Shroads AL, Stacpoole PW. Inhibition of glutathione S-transferase zeta and tyrosine metabolism by dichloroacetate: a potential unifying mechanism for its altered biotransformation and toxicity. Biochem Biophys Res Commun. 1999;262:752–756.
    1. Danpure CJ. Primary hyperoxaluria. In: Scriver C, Beaudet A, Sly W, Valle D, Childs B, Kinzler K, et al., editors. Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York: McGraw-Hill; 2001. pp. 3323–3367.
    1. Evans MV, Chiu WA, Okino MS, Cladwell JC. Development of an updated PBPK model for trichloroethylene and metabolites in mice, and its application to discern the role of oxidative metabolism in TCE-induced hepatomegaly. Toxicol Appl Pharmacol. 2009;236:329–340.
    1. Felitsyn N, McLeod C, Shroads AL, Stacpoole PW, Notterpek L. The heme precursor delta-aminolevulinate blocks peripheral myelin formation. J Neurochem. 2008;106:2068–2079.
    1. Guengerich FP. Metabolism of trichloroethylene and covalent binding of reaction products. Proceedings of Symposium on New Scientific Research Related to the Health Effects of Trichloroethylene; 26–27 February, 2004; Washington, DC. 2004. [[accessed 19 December 2010].]. Available: .
    1. Guo X, Dixit V, Lui H, Shroads AL, Henderson AL, James MO, et al. Inhibition and recovery of rat hepatic glutathione S-transferase zeta and alteration of tyrosine metabolism following dichloroacetate treatment and withdrawal. Drug Metab Dispos. 2006;34:36–42.
    1. Henderson GN, Curry SH, Derendorf H, Wright EC, Stacpoole PW. Pharmacokinetics of dichloroacetate in adult patients with lactic acidosis. J Clin Pharmacol. 1997;37:416–425.
    1. IARC (International Agency for Research on Cancer) Dichloroacetic acid. IARC Monogr Eval Carcinog Risks Hum. 2004;84:359–402.
    1. James MO, Yan Z, Cornett R, Jayanti VM, Henderson GN, Davydova N, et al. Pharmacokinetics and metabolism of [14C]-dichloroacetate (DCA) in the male Sprague-Dawley rats: identification of glycine conjugates, including hippurate, as urinary metabolites of dichloroacetate. Drug Metab Dispos. 1998;26:1134–1143.
    1. Jia M, Coats BS, Chadha M, Frentzen B, Perez-Rodriguez J, Chadik PA, et al. Human kinetics of orally and intravenously administered low dose 1, 2-13C-dichloroacetate. J Clin Pharmacol. 2006;46:1449–1459.
    1. Kaufmann P, Engelstad K, Wei Y, Jhung S, Sano MC, Shungu DC, et al. Dichloroacetate causes toxic neuropathy in MELAS: a randomized, controlled clinical trial. Neurology. 2006;66:324–330.
    1. Ketcha MM, Stevens DK, Warren DA, Bishop CT, Brashear WT. Conversion of trichloroacetic acid to dichloroacetic acid in biological samples. J Anal Toxicol. 1996;20:236–241.
    1. Lantum HB, Liebler DC, Board PG, Anders MW. Alkylation and inactivation of human glutathione transferase zeta (hGSTZ1-1) by maleylacetone and fumarylacetone. Chem Res Toxicol. 2002;15:707–716.
    1. Lash LH, Fisher JW, Lipscomb JC, Parker JC. Metabolism of trichloroethylene. Environ Health Perspect. 2000;108:177–200.
    1. Lee JH, Chung CW, Ma YC, Wang GS, Chen PC, Hwang YH, et al. Increased mortality odds ratio of male liver cancer in a community contaminated by chlorinated hydrocarbons in groundwater. Occup Environ Med. 2003;60:364–369.
    1. Li W, James MO, McKenzie S, Stacpoole PW. Mitochondrion is a novel site of biotransformation of dichloroacetate by glutathione transferase zeta1. J Pharmacol Exp Ther. 2011;330:87–94.
    1. Lim CE, Matthaei KI, Blackburn AC, Davis RP, Dahlstrom JE, Koina ME, et al. Mice deficient in glutathione transferase zeta/maleylacetoacetate isomerase exhibit a range of pathological changes and elevated expression of alpha, mu, and pi class glutathione transferases. Am J Pathol. 2004;165:679–693.
    1. Lindberg RL, Martini R, Baumgartner M, Erne B, Borg J, Zielasek J, et al. Motor neuropathy in porphobilinogen deaminase-deficient mice imitates the peripheral neuropathy of human acute porphyria. J Clin Invest. 1999;103:1127–1134.
    1. McMurtry MS, Bonnet S, Wu X, Dyck JR, Haromy A, Hashimoto K, et al. Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis. Circ Res. 2004;95:830–840.
    1. Merdink JL, Gonzalez-Leon A, Bull RJ, Schultz IR. The extent of dichloroacetate formation from trichloroethylene, chloral hydrate, trichloroacetate, and trichloroethanol in B6C3F1 mice. Toxicol Sci. 1998;45:33–41.
    1. Michelakis ED, McMurtry MS, Wu XC, Dyck JR, Moudgil R, Hopkins TA, et al. Dichloroacetate, a metabolic modulator, prevents and reverses chronic hypoxic pulmonary hypertension in rats: role of increased expression and activity of voltage-gated potassium channels. Circulation. 2002;105:244–250.
    1. Michelakis ED, Sutendra G, Dromparis P, Webster L, Harmony A, Niven E, et al. Metabolic modulation of glioblastoma with dichloroacetate. Sci Trans Med. 2010;2:31–34.
    1. Michelakis ED, Webster L, Mackey JR. Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br J Cancer. 2008;99:989–994.
    1. Miller JW, Uden PC. Characterization of nonvolatile aqueous chlorination products of humic substances. Environ Sci Technol. 1983;17:150–157.
    1. Mitchell GA, Grompe M, Lambert M, Tanguay RM. Hypertyrosinemia. In: Scriver C, Beaudet A, Sly W, Valle D, Childs B, Kinzler K, Vogelstein B, editors. Metabolic and Molecular Bases of Inherited Disease. 8th edition. II. New York: McGraw-Hill; 2001. pp. 1777–1806.
    1. Obolensky A, Shukairy H, Blank V. Occurrence of haloacetic acids in ICR finished water and distribution systems. In: McGuire MJ, McLain JL, Obolensky A, editors. Information Collection Rule Analysis Data. Denver, CO: AWWA Research Foundation; 2003. pp. 111–140.
    1. Saghir SA, Schultz IR. Low-dose pharmacokinetics and oral bioavailability of dichloroacetate in naive and GST-zeta-depleted rats. Environ Health Perspect. 2002;110:757–763.
    1. Sassa S, Kappas A. Hereditary tyrosinemia and the heme biosynthetic pathway. Profound inhibition of delta-aminolevulinic acid dehydratase activity by succinylacetone. J Clin Invest. 1983;71:625–634.
    1. Schultz IR, Merdink JL, Gonzalez-Leon A, Bull RJ. Dichloroacetate toxicokinetics and disruption of tyrosine catabolism in B6C3F1 mice: dose-response relationships and age as a modifying factor. Toxicology. 2002;173:229–247.
    1. Schultz IR, Shangraw RE. Effect of short-term drinking water exposure to dichloroacetate on its pharmacokinetics and oral bioavailability in human volunteers: a stable isotope study. Toxicol Sci. 2006;92:42–50.
    1. Scriver R, Levy H, Donlon J. Hyperphenylalaninemia: phenylalanine hydroxylase deficiency. In: Scriver C, Beaudet A, Sly W, Valle D, Childs B, Kinzler K, et al., editors. Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York: McGraw-Hill; 2001. pp. 1667–1724.
    1. Shroads AL, Guo X, Dixit V, Liu H-P, James MO, Stacpoole PW. Age-dependent metabolism of dichloroacetate in rats: possible relevance to human toxicity. J Pharmacol Exp Ther. 2008;324:1163–1171.
    1. Stacpoole PW. The pharmacology of dichloroacetate. Metabolism. 1989;38:1124–1144.
    1. Stacpoole PW, Henderson GN, Yan Z, Cornett R, James MO. Pharmacokinetics, metabolism and toxicology of dichloroacetate. Drug Metab Rev. 1998b;30:499–539.
    1. Stacpoole PW, Henderson GN, Yan Z, James MO. Clinical pharmacology and toxicology of dichloroacetate. Environ Health Perspect. 1998a;106:989–994.
    1. Stacpoole PW, Kerr DS, Barnes C, Bunch ST, Carney PR, Fennell EM, et al. A controlled clinical trial of dichloroacetate for treatment of congenital lactic acidosis in children. Pediatrics. 2006;117:1519–1531.
    1. Stacpoole PW, Kurtz TL, Han Z, Langaee T. Role of dichloroacetate in the treatment of genetic mitochondrial diseases. Adv Drug Deliv Rev. 2008;60:1478–1487.
    1. Stacpoole PW, Wright EC, Baumgartner TG, Bersin RM, Buchalter S, Curry SH, et al. A controlled clinical trial of dichloroacetate treatment of lactic acidosis in adults. The Dichloroacetate-Lactic Acidosis Study Group. N Engl J Med. 1992;327:1564–1569.
    1. Sugden MC, Holness MJ. Recent advances in mechanisms regulating glucose oxidation at the level of the pyruvate dehydrogenase complex by PDKs. Am J Physiol Endocrinol Metab. 2003;284:E855–E862.
    1. Templin MV, Stevens DK, Stenner RD, Bonate PL, Tuman D, Bull RJ. Factors affecting species differences in the kinetics of metabolites of trichloroethylene. J Toxicol Environ Health. 1995;44:435–447.
    1. Tzeng HF, Blackburn AC, Anders MW. Polymorphism- and species-dependent inactivation of glutathione transferase zeta by dichloroacetate. Chem Res Toxicol. 2000;13:231–236.
    1. U.S. Geological Survey. Volatile Organic Compounds in the Nation’s Ground Water and Drinking-Water Supply Wells. Circular 1292. Reston, VA: U.S. Geological Survey; 2006.
    1. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324:1029–1033.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren